Latest Investments News

BetMakers Technology Group has successfully raised $11.5 million through a share placement aimed at repaying debt and funding strategic growth initiatives, including a potential acquisition in Nevada.

Aureka Limited has raised $3 million through a share placement to accelerate exploration and secure land access at its key gold projects in Victoria, signalling strong investor confidence in its growth strategy.

Hawsons Iron Limited is raising up to $1 million through a discounted Share Purchase Plan to fund critical project development while continuing strategic investor discussions.

MPower Group has struck a deal to sell nearly all its renewable energy assets to Wollemi Energy Group for about $19 million, unlocking significant shareholder value and setting the stage for a strategic reset.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

AGL Energy has confirmed it is reviewing its 20% stake in Tilt Renewables following recent media speculation, though no sale discussions are underway. The outcome remains uncertain as the company conducts preliminary assessments.

JPMorgan Asset Management has announced the June 2025 distribution and provided detailed tax attribution estimates for its US 100Q Equity Premium Income Active ETF, highlighting key income components and withholding tax implications.

Southern Palladium has raised A$8 million through a strategic placement to accelerate its Definitive Feasibility Study and staged mine development at the Bengwenyama PGM project, backed by a major cornerstone investor.

McLaren Minerals has successfully raised $1.282 million through a two-tranche placement to advance its McLaren Titanium Project in Western Australia, aiming to complete a critical pre-feasibility study by early Q3 2025.

ASX Limited’s 2025 Investor Forum reveals steady progress on its five-year strategy, highlighting technology modernization, operational risk management, and a focus on data-driven growth. The exchange outlines capital expenditure plans and expense controls aimed at sustaining shareholder value amid evolving market demands.

ASX Limited reveals steady progress on its FY28 strategy, emphasizing technology modernization and operational resilience while providing detailed financial guidance through FY27.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.